162 related articles for article (PubMed ID: 25003571)
1. The use of obinutuzumab in chronic lymphocytic leukemia.
Wierda W
Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
[No Abstract] [Full Text] [Related]
2. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
[No Abstract] [Full Text] [Related]
3. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
Rogers KA; Jones JA
Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib: searching for a partner drug.
Kater AP; Brown JR
Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
[No Abstract] [Full Text] [Related]
6. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
Jean GW; Comeau JM
Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
8. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
Pitini V; Cascio A; Arrigo C; Altavilla G
Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529
[No Abstract] [Full Text] [Related]
9. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
Shah A
Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab looks impressive in CLL.
Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
[No Abstract] [Full Text] [Related]
12. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
14. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Cramer P; von Tresckow J; Fink AM; Robrecht S; Giza A; Tausch E; Müller L; Knauf W; Zingerle M; Al-Sawaf O; Langerbeins P; Fischer K; Kreuzer KA; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Am J Hematol; 2024 Jun; 99(6):1192-1195. PubMed ID: 38578022
[No Abstract] [Full Text] [Related]
16. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Langerak AW; Ritgen M; Goede V; Robrecht S; Bahlo J; Fischer K; Steurer M; Trněný M; Mulligan SP; Mey UJM; Trunzer K; Fingerle-Rowson G; Humphrey K; Stilgenbauer S; Böttcher S; Brüggemann M; Hallek M; Kneba M; van Dongen JJM
Blood; 2019 Jan; 133(5):494-497. PubMed ID: 30455380
[No Abstract] [Full Text] [Related]
17. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Freeman CL; Morschhauser F; Sehn L; Dixon M; Houghton R; Lamy T; Fingerle-Rowson G; Wassner-Fritsch E; Gribben JG; Hallek M; Salles G; Cartron G
Blood; 2015 Dec; 126(24):2646-9. PubMed ID: 26447188
[No Abstract] [Full Text] [Related]
18. Obinutuzumab in chronic lymphocytic leukemia.
Dupuis J
Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
Hoy SM
Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K; Al-Sawaf O; Fink AM; Dixon M; Bahlo J; Warburton S; Kipps TJ; Weinkove R; Robinson S; Seiler T; Opat S; Owen C; López J; Humphrey K; Humerickhouse R; Tausch E; Frenzel L; Eichhorst B; Wendtner CM; Stilgenbauer S; Langerak AW; van Dongen JJM; Böttcher S; Ritgen M; Goede V; Mobasher M; Hallek M
Blood; 2017 May; 129(19):2702-2705. PubMed ID: 28325865
[No Abstract] [Full Text] [Related]
[Next] [New Search]